Active receptors and G proteins communicate in real time, not as separate components
Deep within the membranes of our cells, molecular switches have long governed how we perceive the world and how our bodies respond to it — yet the precise choreography of their activation has remained hidden from science until now. A team of South Korean researchers at DGIST has built a fluorescent biosensor capable of watching, in real time, the moment a G-protein coupled receptor springs to life and sets a cellular cascade in motion. Their discovery, published in Nature Communications in March 2023, reveals not a single flip of a switch but a two-step molecular dance — one with profound implications for understanding cancer, neurological disease, and the future of drug design. In seeing what was once invisible, science moves closer to intervening where it matters most.
- Nearly half of all known drugs target GPCRs, yet the real-time mechanics of their activation have remained a blind spot in biology — until now.
- The new biosensor exposed an unexpected two-step process: a rapid G-protein binding phase followed by a slower, consequential subunit separation that carries the signal deeper into the cell.
- Mutations in G-protein genes linked to uveal melanoma revealed a troubling behavior — separated subunits can independently loop back and rebind the receptor, offering a new lens on how cancer-driving mutations operate.
- The research reframes drug design strategy: rather than targeting receptors or G proteins in isolation, therapies could now be aimed at the precise moment and manner of their interaction.
- Led by Professor Byung-Chang Suh and doctoral student Yong-Seok Kim, the work transforms a long-held theoretical model of cellular signaling into something observable, measurable, and actionable.
Inside every cell, molecular switches sit at the membrane's edge, waiting for signals — the scent of coffee, a surge of hormone, the warmth of light. These are G-protein coupled receptors, or GPCRs, and they govern an extraordinary range of biological responses. Nearly half of all known drugs work by targeting them, yet what actually happens in the moment of their activation has never been clearly seen.
A research team at DGIST in South Korea, led by Professor Byung-Chang Suh, set out to change that. They engineered a biosensor using fluorescent proteins capable of watching the molecular choreography of GPCR activation as it unfolded in real time. Focusing on the human M3 muscarinic acetylcholine receptor, they discovered that activation is not a single event but a two-step transformation: first, a rapid binding of the G protein Gq to the receptor, then a slower separation of the G protein's alpha subunit from its beta-gamma partners. That separated alpha subunit goes on to form a stable complex with both the activated receptor and a downstream signaling protein, carrying the message further into the cell.
The implications extended into disease. When the team examined mutations associated with uveal melanoma, a rare eye cancer, they found that the freed beta-gamma subunits could independently rebind to the receptor — an unexpected behavior that sheds new light on how these mutations drive malignancy and where drugs might intervene.
Published in Nature Communications in March 2023, the work confirms what had long been theoretical: that GPCRs and G proteins operate not as isolated components but as an integrated, dynamic system. For diseases ranging from cancer to neurological and metabolic disorders, the ability to observe this molecular conversation in real time opens a new chapter — one where therapies can be designed not just against a target, but against the precise moment a process goes wrong.
Inside cells, there are molecular switches that respond to the world around us—the smell of coffee, the warmth of sunlight, the presence of a hormone telling your body to act. These switches are called G-protein coupled receptors, or GPCRs, and they sit on the surface of cells waiting for a signal. When that signal arrives, the receptor springs to life, triggering a cascade of events inside the cell. Nearly half of all known drugs work by targeting these receptors, which tells you how central they are to human biology and medicine.
What scientists have never been able to see clearly, until now, is what actually happens in the moment when a GPCR activates. The process involves G proteins—molecular machines that turn on and off in response to the receptor's signal. Researchers knew the two were connected, but the real-time choreography between them remained invisible. A team at DGIST, a research institute in South Korea, led by Professor Byung-Chang Suh, set out to change that. They built a biosensor using fluorescent proteins that could watch this molecular dance as it unfolded.
The team focused on a specific GPCR called the human M3 muscarinic acetylcholine receptor, a receptor involved in muscle contraction and other vital functions. Using their new biosensor, they discovered something unexpected: when a GPCR receives a signal and activates, it doesn't simply flip a switch. Instead, it undergoes a two-step transformation. First comes a rapid phase where a G protein called Gq binds to the receptor. Then comes a slower phase where the G protein splits apart—its alpha subunit separating from its beta-gamma subunits. This separation is crucial. The separated alpha subunit then forms a stable complex with both the activated receptor and a downstream signaling protein called PLCβ, which carries the message deeper into the cell.
What makes this discovery particularly significant is what it reveals about disease. The researchers also investigated mutations in G-protein genes that cause uveal melanoma, a rare form of eye cancer. They found that the beta-gamma subunits, once separated from the alpha subunit, can independently bind back to the receptor. This unexpected behavior provides a new angle for understanding how these genetic mutations drive disease and, more importantly, how drugs might be designed to interrupt that process.
Professor Suh described the work as confirming something that had long been theoretical: that active GPCRs and G proteins communicate in real time, not as separate, isolated components but as an integrated system. The research was published in Nature Communications in March 2023, with Yong-Seok Kim, a doctoral student in the Department of Brain Sciences, as the lead author. The work was supported by the South Korean National Research Foundation.
The implications ripple outward. If you can see how these molecular switches work in real time, you can begin to understand what goes wrong when they malfunction. You can design drugs that target not just the receptor or the G protein alone, but the precise moment and manner of their interaction. For diseases ranging from cancer to neurological disorders to metabolic dysfunction—all of which involve GPCR signaling—this kind of molecular-level visibility opens new doors. The next phase is to translate this understanding into therapies that work.
Citas Notables
We confirmed the real-time communication between active GPCRs and G proteins, which had been considered separate up to this point.— Professor Byung-Chang Suh
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that we can now see this happening in real time? Couldn't researchers already study these receptors and proteins?
They could study them, but only in snapshots—like looking at a photograph of a dancer mid-leap. You see the position, but not the motion. Real time means watching the actual sequence unfold, seeing which step happens first, how long each step takes, and what comes next. That timing and order is everything in biology.
And what did they actually discover that was new?
That the process has two distinct phases. The G protein doesn't just bind and stay bound. It binds, then it splits apart. And that splitting apart—that's when the real signaling work begins. Nobody had seen that clearly before.
You mentioned this could help with cancer. How does a molecular switch relate to uveal melanoma?
Mutations in G-protein genes can cause that cancer. The researchers found that when the G protein splits, the separated pieces can still interact with the receptor in unexpected ways. If you understand those interactions, you can potentially block them with a drug.
So this is a tool for drug makers?
It's a tool for understanding. Drug makers will come later. But yes, once you can see exactly how a broken system misbehaves at the molecular level, you can design something to fix it.
How long until we see drugs based on this?
That's the long game. This is foundational science. It opens the door, but the door opening and walking through it are different things.